Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Grzegorz Kijanka"'
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e85281 (2014)
Protein aggregates are a major risk factor for immunogenicity. Until now most studies on aggregate-driven immunogenicity have focused on linking physicochemical features of the aggregates to the formation of anti-drug antibodies. Lacking is however,
Externí odkaz:
https://doaj.org/article/8f13435971424eb6882d96c10e83a92b
Autor:
Bram Slütter, Jared S. Bee, Samuel A. Korman, Wim Jiskoot, Mark A. Schenerman, Yuling Wu, Grzegorz Kijanka
Publikováno v:
Journal of Pharmaceutical Sciences
Journal of Pharmaceutical Sciences, 109(1), 730-738
Journal of Pharmaceutical Sciences, 109(1), 730-738
The presence of protein aggregates is commonly believed to be an important risk factor for immunogenicity of therapeutic proteins. Among all types of aggregates, dimers are relatively abundant in most commercialized monoclonal antibody (mAb) products
Autor:
De-xiu Bu, Harald Kropshofer, Francis Kinderman, Grzegorz Kijanka, Vibha Jawa, Lora Hamuro, Monica L. Zepeda
Publikováno v:
Journal of Pharmaceutical Sciences. 106:2946-2954
An increasing number of therapeutic proteins are being developed for delivery through the subcutaneous (SC) route of administration. Relative to intravenous (IV) administration, the SC route offers more convenience to patients, flexibility in dosing,
Publikováno v:
Pharmaceutical Biotechnology: Fundamentals and Applications, 139-150
STARTPAGE=139;ENDPAGE=150;TITLE=Pharmaceutical Biotechnology
Pharmaceutical Biotechnology ISBN: 9783030007096
STARTPAGE=139;ENDPAGE=150;TITLE=Pharmaceutical Biotechnology
Pharmaceutical Biotechnology ISBN: 9783030007096
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dbb7eb6da12c79509564c1dfd216303
https://pure.amc.nl/en/publications/immunogenicity-of-therapeutic-proteins(5b5a1b09-5c34-4c90-9972-49b7155d1e3a).html
https://pure.amc.nl/en/publications/immunogenicity-of-therapeutic-proteins(5b5a1b09-5c34-4c90-9972-49b7155d1e3a).html
Autor:
Yuling Wu, Lorin Roskos, Wim Jiskoot, Grzegorz Kijanka, Bram Slütter, Jared S. Bee, Mark A. Schenerman, Samuel A. Korman
Publikováno v:
Journal of Pharmaceutical Sciences, 107(11), 2874-2859
Journal of Pharmaceutical Sciences
Journal of Pharmaceutical Sciences
Protein aggregates are one of several risk factors for undesired immunogenicity of biopharmaceuticals. However, it remains unclear which features determine whether aggregates will trigger an unwanted immune response. The aim of this study was to dete
Publikováno v:
Pharmaceutical Research. 30:1553-1560
Interferon beta is commonly used as therapeutic in the first line of therapy for multiple sclerosis. However, depending on the product, it induces an antibody response in up to 60% of patients. This study evaluated the impact of therapy related facto
Publikováno v:
Journal of pharmaceutical sciences
Journal of Pharmaceutical Sciences, 105(5), 1693-1704
Journal of Pharmaceutical Sciences, 105(5), 1693-1704
The aim of this study was to examine the fate of differently sized protein aggregates upon subcutaneous injection in mice. A murine and a human monoclonal immunoglobulin G 1 (IgG1) antibody were labeled with a fluorescent dye and subjected to stress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddd9c85c35c7ffacf6d0e3388628050d
https://doi.org/10.1016/j.xphs.2016.02.034
https://doi.org/10.1016/j.xphs.2016.02.034
Autor:
Marisa K. Joubert, Theodore W. Randolph, Grzegorz Kijanka, John F. Carpenter, Atanas Koulov, Hanns-Christian Mahler, Wim Jiskoot, Linda O. Narhi, Vibha Jawa
The success of clinical and commercial therapeutic proteins is rapidly increasing, but their potential immunogenicity is an ongoing concern. Most of the studies that have been conducted over the past few years to examine the importance of various pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99bb0aaaa1aa58a1023ce0bc24d0f39a
http://hdl.handle.net/1887/3198079
http://hdl.handle.net/1887/3198079
Autor:
Miranda M. C. van Beers, Huub Schellekens, Wim Jiskoot, Vera Brinks, Louis Boon, Grzegorz Kijanka, Melody Sauerborn
Publikováno v:
Journal of clinical immunology. 33(1)
The immunological processes underlying immunogenicity of recombinant human therapeutics are poorly understood. Using an immune tolerant mouse model we previously demonstrated that aggregates are a major trigger of the antidrug antibody (ADA) response
Publikováno v:
Postepy biochemii. 55(4)
Erythrocytes can occur in many different shapes. Most of them are pathological and can be involved in diseases such a hemolytic anemia's and sickle cell anemia. Only three kinds of red blood cells are no pathological. Echinocytes, stomatocytes and di